title: The analgesic effects and mechanisms of orally administered eugenol.
abstract: In the present study, the antinociceptive profiles of eugenol were examined in ICR mice. Eugenol administered orally (from 1 to 10 mg/kg) showed an antinociceptive effect in a dose-dependent manner as measured in the acetic acid-induced writhing test. Duration of antinociceptive action of eugenol maintained at least for 30 min. Moreover, the cumulative response time of nociceptive behaviors induced by an intraplantar formalin injection was reduced by eugenol treatment during the 2(nd) phases. Furthermore, the cumulative nociceptive response time for intrathecal injection of substance P (0.7 μg) or glutamate (20 μg) was diminished by eugenol. Intraperitoneal pretreatment with yohimbine (α2-adrenergic receptor antagonist) or naloxone (opioid receptor antagonist) attenuated antinociceptive effect induced by eugenol in the writhing test. However, methysergide (5-HT serotonergic receptor antagonist) did not affect antinociception induced by eugenol in the writhing test. Our results suggest that eugenol shows an antinociceptive property in various pain models. Furthermore, this antinociceptive effect of eugenol may be mediated by α2-adrenergic and opioidergic receptors, but not serotonergic receptor.
authors.affiliation: Department of Pharmacology, Institute of Natural Medicine, College of Medicine, Hallym University, Chuncheon, Korea.
authors.forename: Soo-Hyun
authors.initials: SH
authors.lastname: Park
authors.forename: Yun-Beom
authors.initials: YB
authors.lastname: Sim
authors.forename: Jin-Koo
authors.initials: JK
authors.lastname: Lee
authors.forename: Seon-Mi
authors.initials: SM
authors.lastname: Kim
authors.forename: Yu-Jung
authors.initials: YJ
authors.lastname: Kang
authors.forename: Jun-Sub
authors.initials: JS
authors.lastname: Jung
authors.forename: Hong-Won
authors.initials: HW
authors.lastname: Suh
mesh_terms: D019342:Acetic Acid / Q000494:pharmacology; D000284:Administration, Oral; D000700:Analgesics / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D004195:Disease Models, Animal; D005054:Eugenol / Q000008:administration & dosage / Q000627:therapeutic use*; D018698:Glutamic Acid / Q000494:pharmacology; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D010146:Pain / Q000188:drug therapy* / Q000503:physiopathology; D010147:Pain Measurement; D018341:Receptors, Adrenergic, alpha-2 / Q000378:metabolism; D011957:Receptors, Opioid / Q000378:metabolism; D011985:Receptors, Serotonin / Q000378:metabolism; D013373:Substance P / Q000494:pharmacology
chemical_list: D000700:Analgesics; D018341:Receptors, Adrenergic, alpha-2; D011957:Receptors, Opioid; D011985:Receptors, Serotonin; D013373:Substance P; D018698:Glutamic Acid; D005054:Eugenol; D019342:Acetic Acid